Glaceum Inc.
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- Parkinson's clinical phase 2a in progress and scheduled to end in 2026Q1
- Vutiglabridin is a first-in-class PON2 modulator that activates autophagy
- Vutiglabridin is a once daily small molecule drug
Glaceum is seeking to out-license or investment.
)
)
){kind=logo}
){kind=logo}
){kind=logo}